



Occurrence and outcome of hepatitis C reinfections in opioid agonist therapy patients of the SAMMSU cohort

Bregenzer A¹, Bruggmann P², Castro E³, Della Santa P⁴, Hensel-Koch K⁵, Moriggia A^{6,7}, Thurnheer MC⁸, Scheidegger C⁹

¹Department of Infectious Diseases and Infection Prevention, Cantonal Hospital Aarau, ²Arud Centre for Addiction Medicine, Zurich, ³Private Practice, Lausanne, ⁴Fondation Phénix, Geneva, ⁵Stiftung Suchthilfe, St. Gallen, ⁶Ingrado Servizi per le Dipendenze, Lugano, ⁷Epatocentro Ticino SA, Lugano, ⁸Department of Infectious Diseases, University Hospital, Bern, ⁹Independent, Basel

BACKGROUND

- Direct-acting antivirals (DAAs), achieving chronic hepatitis C cure rates of nearly 100%, are reimbursed without liver fibrosis restriction in Switzerland since 2017.
- However, a high reinfection rate could hamper HCV elimination efforts.

Figure 3: Occurrence of reinfections: year of diagnosis (n=48)

	9 -	(GSL) (NXT) 7916	
S	8 -	after SVR, IFN-free (n=12)	
	7 -	■ after SVR, IFN-based (n=21)	

METHODS


- Between 2014 and 02/03/2023, the Swiss Association for the Medical Management in Substance Users (SAMMSU) cohort has recruited 1346 >18-yearold opioid agonist therapy (OAT) patients (75% ever intravenous drug use, 59% HCV-antibody-positive, yearly follow-up).
- For Figure 1-3, data derived from a specific "reinfection form" within the database, whereas for Table 1+2 time-to-event analyses were used considering only the first successful treatment in each patient, resulting in slightly different numbers.
- Regarding the reinfection rate, follow-up time was from the end-of-treatment to the first positive HCV-RNA or the last negative HCV-RNA, if no reinfection occurred.

RESULTS – Occurence of reinfections after spontaneous clearance / treatment

 Among the 48 reinfections in 44 patients documented within the SAMMSU cohort, 31% (15) were after spontaneous clearance (SC), 44% (21) after IFN-based and 25% (12) after IFN-free HCV-treatment (Figure 1, Figure 3).

Figure 1: Occurrence of reinfections after spontaneous clearance / treatment (n=48)

25% 31%
 after SVR, IFN-based (n=21)




SC = spontaneous clearance, SVR = sustained virological response, IFN = interferon Status: 02.03.2023, 48 reinfections in 44 patients; Data source: specific "reinfection form"

RESULTS – Cumulative reinfection rate after treatment

- Between 1988 and 02/03/2023, 33 HCV reinfections occurred in 486 successfully treated patients (median follow-up time: 2.82 (IQR: 0.94-5.00) years, cumulative reinfection rate: 6.8%).
- The cumulative reinfection rate was 17.1% (20/117) after IFN-based and 3.5% (13/369) after IFN-free treatment (p<0.001) (**Table 1**).

 Table 1: Cumulative reinfection rate after successful treatment

	Observation period	Reinfections after SVR (n)		Cumulative reinfection rate (%)	95% CI
IFN-based	1988*-2023	20	117	17.1	11.4-24.9
IFN-free	2013#-2023	13	369	3.5	2.1-5.9
Total	1988-2023	33	486	6.8	4.9-9.4



SC = spontaneous clearance, SVR = sustained virological response, IFN = interferon; Data source: specific "reinfection form"

RESULTS – Chronification rate after reinfection

The proportion of patients developing chronic infection was significantly lower after spontaneous clearance than after successful treatment (60% (9/15) versus 94% (31/33), p<0.001), with no difference between IFN-based and IFN-free treatment (90% (19/21) versus 100% (12/12), p=0.270) (Figure 2).




Figure 2: Chronification rate after reinfection according to treatment history (n=48)

SVR = sustained virological response, IFN = interferon, CI = confidence interval, *end of first successful IFN-based HCV treatment in the SAMMSU cohort, #end of first successful IFN-free HCV treatment in the SAMMSU cohort, Data source: time-to-event analyses considering only the first successful treatment in each patient

RESULTS – Reinfection rate after treatment

- With a total follow-up time of 1904.16 years, the reinfection rate was 1.73 (95% CI: 1.23-2.44)/100 person-years (Table 2).
- It was similar after IFN-based and IFN-free treatment (1.98 (95% CI: 1.28-3.07) versus 1.45 (95% CI: 0.84-2.51)/100 person-years, p=0.385).
- Total follow-up time was 1010.46 years after IFN-based treatment (median: 7.60 (IQR: 4.26-11.52) years) and 893.69 years after IFN-free treatment (median: 2.25 (IQR: 0.63-3.70) years).

Table 2: Reinfection rate after successful treatment

	Median FUP-time (y) (95% CI)	Reinfections after SVR (n)	Total FUP-time (y)	Reinfection rate (per 100 PY)	95% CI
IFN-based	7.6 (4.3-11.5)	20	1010.46	1.98	1.28-3.07
IFN-free	2.3 (0.6-3.7)	13	893.69	1.45	0.84-2.51
Total	2.8 (0.9-5.0)	33	1904.16	1.73	1.23-2.44

after SC after SVR, after SVR, after SVR, total IFN-based IFN-free

SC = spontaneous clearance, SVR = sustained virological response, IFN = interferon; The error bars show the lower and upper limit of the 95% confidence interval (Score(Wilson)). Data source: specific "reinfection form"

ACKNOWLEDGEMENT/SPONSORING

 SAMMSU has been financed by Infodrog (on behalf of Swiss Federal Office of Public Health), Pharma industries (BMS, Abbvie, Gilead, Merck, Roche), SSAM (Swiss Society for Addiction Medicine), SEVHep (Swiss Experts in Viral Hepatitis), Inselspital Bern, Kantonsspital St. Gallen, Kantonsspital Aarau, Arud Zentrum für Suchtmedizin, Zfs Zentrum für Suchtmedizin Basel, Universitätsspital Zürich. FUP = follow-up, y = years, SVR = sustained virological response, IFN = interferon, CI = confidence interval; Data source: time-to-event analyses considering only the first successful treatment in each patient

CONCLUSIONS

- With a low reinfection rate of <2 per 100 person-years, reinfections do not compromise HCV elimination efforts in Swiss OAT-patients.
- While >90% of patients reinfected after successful HCV treatment develop chronic infection, patients reinfected after spontaneous clearance should be monitored regarding another spontaneous clearance.

Contact information: Dr. med. Andrea Bregenzer, Cantonal Hospital Aarau, Tellstrasse 25, CH-5000 Aarau, Switzerland andrea.bregenzer@ksa.ch www.sammsu.ch